These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32749624)

  • 21. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of IDH and TERTp mutation status using
    Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A
    J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Zhang Z; Chan AK; Ding X; Li Y; Zhang R; Chen L; Liu Y; Wang Y; Xiong J; Ng HK; Yao Y; Zhou L
    Neuro Oncol; 2017 Jul; 19(7):1008-1010. PubMed ID: 28874004
    [No Abstract]   [Full Text] [Related]  

  • 24. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
    Fan X; Wang Y; Liu Y; Liu X; Zhang C; Wang L; Li S; Ma J; Jiang T
    J Neurooncol; 2016 Jul; 128(3):455-62. PubMed ID: 27230769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
    Otsuji K; Sasaki T; Tanabe M; Seto Y
    Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
    Masui K; Komori T; Kato Y; Masutomi K; Ichimura K; Ogasawara S; Kaneko MK; Oki H; Suzuki H; Nitta M; Maruyama T; Muragaki Y; Kawamata T; Sawada T; Shibata N
    Biomed Res Int; 2018; 2018():7945845. PubMed ID: 29693015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.
    Lee J; Putnam AR; Chesier SH; Banerjee A; Raffel C; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Perry A; Solomon DA
    Acta Neuropathol Commun; 2018 Sep; 6(1):95. PubMed ID: 30231927
    [No Abstract]   [Full Text] [Related]  

  • 28. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
    Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
    Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Evolution of
    Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
    J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
    Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
    Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
    Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.
    Kovács Á; Sükösd F; Kuthi L; Boros IM; Vedelek B
    Clin Exp Med; 2024 Aug; 24(1):192. PubMed ID: 39141194
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Kikuchi Z; Shibahara I; Yamaki T; Yoshioka E; Shofuda T; Ohe R; Matsuda KI; Saito R; Kanamori M; Kanemura Y; Kumabe T; Tominaga T; Sonoda Y
    Neurooncol Adv; 2020; 2(1):vdaa114. PubMed ID: 33134923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable prognostic impact of
    Higa N; Akahane T; Yokoyama S; Makino R; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Noguchi N; Otsuji R; Kuga D; Nagasaka S; Yamahata H; Yamamoto J; Yoshimoto K; Tanimoto A; Hanaya R
    Neurooncol Adv; 2023; 5(1):vdad078. PubMed ID: 37528810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.